Skip to main content

Accelerating the Development of New Drugs and Diagnostics Maximizing the Impact of the Cures Acceleration Network: Workshop Summary (2012) / Chapter Skim
Currently Skimming:

3 Application of Matching Authority
Pages 29-38

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 29...
... a Identified by individual speakers. The section of the CAN authorizing legislation establishing the Cures Acceleration Partnership Awards states: "An eligible entity shall contribute to the project non-Federal funds in the amount of $1 for every $3 awarded .
Read the entire page →
From page 30...
... Phase III is the commercialization stage. It is expected to be done by companies using funds separate from the SBIR programs, whether from venture capital, another company, or some other strategic partner.
Read the entire page →
From page 31...
... Weingarten concentrated specifically on the part of the SBIR program at NCI known as a Phase II Bridge Award, which addresses the gap, or valley of death, between Phase II and commercialization. The Bridge Awards are intended to help companies that were getting promising results from SBIR funds in Phase II but find that they are running out of capital before they are able to commercialize those results.
Read the entire page →
From page 32...
... Weingarten pointed to the special review potential Bridge Award projects undergo as a key to the program's success. Review panels include venture capitalists, clinicians, pharmaceutical industry professionals, and academics.
Read the entire page →
From page 33...
... is a taxpayer-supported research institute approved by California voters in 3The legislation provides that up to 10 percent of the award can go to cancer prevention. 4This section, including subsections, is based on the presentation by Ellen Feigal, Senior Vice President, R&D, California Institute for Regenerative Medicine (CIRM)
Read the entire page →
From page 34...
... CIRM has so far allocated $1.3 billion of its $3 billion total budget. Matching Requirements at CIRM Feigal discussed CIRM's use of a matching authority in four areas: facilities; translational and developmental research programs; collaborative funding programs; and leveraging initiatives with public and private institutions, foundations, industry, and other government agencies.
Read the entire page →
From page 35...
... The CIRM oversight board is determining a new set of disease teams in 2012, which will do preclinical development or conduct and complete clinical trials. While raising matching funds is not required, it is a review criterion, so that proposals that incorporate a match will be more competitive than those without matching.
Read the entire page →
From page 36...
... PERSPECTIVES OF MATCHERS Three representatives of organizations that would be called upon to provide matching funds under CAN provided their perspective on matching requirements for biomedical research. Jens Eckstein, President, SR One, which is the corporate venture arm of GlaxoSmithKline, said that his organization looks for breakthrough innovations in application of the belief that breakthrough innovation will become strategy.
Read the entire page →
From page 37...
... Finally, Michael Gutch, Managing Director, MedImmune Ventures, which is the corporate venture arm of the AstraZeneca Group, said that his organization seeks to build relationships not only with the companies in which it invests but with the companies in which it chooses not to invest. "In the course of a year, we may see 500 deals.
Read the entire page →
From page 38...
... In some sense, venture capitalists are risk averse, in that they try to minimize both financial and regulatory risk by syndicating their investments -- that is, investing alongside others to put less of their capital at risk. Venture capitalists want to partner with foundations, governments, and other organizations, even though those organizations tend to have different agendas.
Read the entire page →

Key Terms

  • venture capital
  • matching requirement
  • cures acceleration
  • matching funds
  • cancer prevention

  • collaborative funding
  • venture capitalists
  • disease teams
  • matching requirements
  • corporate venture

  • funding partners
  • clinical trials
  • bridge award
  • cancer research
  • sbir development

  • innovation research
  • venture arm
  • research teams
  • clinical development
  • sbir program

  • cancer institute
  • strategic partners
  • ellen feigal
  • business innovation
  • clinical trial

  • overall nih
  • pharmaceutical industry
  • preclinical development
  • legislation provides
  • capital firms


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.